Predictive and Prognostic Value of the 21-gene Recurrence Score in Hormone Receptor-positive, Node-positive Breast Cancer

Overview

Journal Am J Clin Oncol

Specialty Oncology

Date 2014 May 24

PMID 24853663

Citations 14

Authors

Adam M Brufsky

Affiliations

Soon will be listed here.

Abstract

The addition of adjuvant chemotherapy to hormonal therapy is recommended for patients with estrogen receptor-positive (ER+), node-positive (N+) early breast cancer (EBC). Some of these patients, however, are not likely to benefit from treatment and may, therefore, be overtreated while also incurring unnecessary treatment-related adverse events and health care costs. The 21-gene Recurrence Score assay has been clinically validated and recommended for use in patients with ER+, node-negative (N0) EBC to assess the 10-year risk of distant disease recurrence and predict the likelihood of response to adjuvant chemotherapy. A growing body of evidence from several large phase III clinical trials reports similar findings in patients with ER+, N+ EBC. A systematic review of published literature from key clinical trials that have used the 21-gene breast cancer assay in patients with ER+, N+ EBC was performed. The Recurrence Score has been shown to be an independent predictor of disease-free survival, overall survival, and distant recurrence-free interval in patients with ER+, N+ EBC. Outcomes from decision impact and health economics studies further indicate that the Recurrence Score affects physician treatment recommendations equally in patients with N+ or N0 disease. It also indicates that a reduction in Recurrence Score-directed chemotherapy is cost-effective. There is a large body of evidence to support the use of the 21-gene assay Recurrence Score in patients with N+ EBC. Use of this assay could help guide treatment decisions for patients who are most likely to receive benefit from chemotherapy.

Citing Articles

Exploring the Genomic Landscape of Hepatobiliary Cancers to Establish a Novel Molecular Classification System.

Scholer A, Marcus R, Garland-Kledzik M, Ghosh D, Ensenyat-Mendez M, Germany J Cancers (Basel). 2024; 16(2).

PMID: 38254814 PMC: 10814719. DOI: 10.3390/cancers16020325.

PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients-a South African cohort study.

Phakathi B, Dix-Peek T, Van Den Berg E, Dickens C, Nietz S, Cubasch H Breast Cancer Res Treat. 2023; 200(3):337-346.

PMID: 37266756 PMC: 10300149. DOI: 10.1007/s10549-023-06969-1.

Behaviour within a Clinical Trial and Implications for Mammography Guidelines.

Kowalski A Rev Econ Stud. 2023; 90(1):432-462.

PMID: 36798741 PMC: 9928190. DOI: 10.1093/restud/rdac022.

RET in breast cancer: pathogenic implications and mechanisms of drug resistance.

Lo Nigro C, Rusmini M, Ceccherini I Cancer Drug Resist. 2022; 2(4):1136-1152.

PMID: 35582269 PMC: 9019211. DOI: 10.20517/cdr.2019.66.

Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX.

Sengupta A, Gunda A, Malpani S, Serkad C, Basavaraj C, Bapat A Cancer Med. 2020; 9(21):7810-7818.

PMID: 33027559 PMC: 7643688. DOI: 10.1002/cam4.3495.

References

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

Hornberger J, Chien R, Krebs K, Hochheiser L . US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer. J Oncol Pract. 2011; 7(3 Suppl):e38s-45s. PMC: 3092466. DOI: 10.1200/JOP.2011.000303. View

Habel L, Shak S, Jacobs M, Capra A, Alexander C, Pho M . A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 2006; 8(3):R25. PMC: 1557737. DOI: 10.1186/bcr1412. View

Wood W, Anderson M, Lyles R, Styblo T, Murray D, Staley C . Can we select which patients with small breast cancers should receive adjuvant chemotherapy?. Ann Surg. 2002; 235(6):859-62. PMC: 1422516. DOI: 10.1097/00000658-200206000-00014. View

Simon R, Paik S, Hayes D . Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009; 101(21):1446-52. PMC: 2782246. DOI: 10.1093/jnci/djp335. View

Eiermann W, Rezai M, Kummel S, Kuhn T, Warm M, Friedrichs K . The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. Ann Oncol. 2012; 24(3):618-24. PMC: 3574549. DOI: 10.1093/annonc/mds512. View

Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier A, Cowens J . Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol. 2013; 31(22):2783-90. DOI: 10.1200/JCO.2012.46.1558. View

Bartlett J, Thomas J, Ross D, Seitz R, Ring B, Beck R . Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. Breast Cancer Res. 2010; 12(4):R47. PMC: 2949634. DOI: 10.1186/bcr2604. View

Lyman G, Cosler L, Kuderer N, Hornberger J . Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer. 2007; 109(6):1011-8. DOI: 10.1002/cncr.22506. View

10.

Albain K, Barlow W, Shak S, Hortobagyi G, Livingston R, Yeh I . Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2009; 11(1):55-65. PMC: 3058239. DOI: 10.1016/S1470-2045(09)70314-6. View

11.

Ross D, Kim C, Tang G, Bohn O, Beck R, Ring B . Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials. Clin Cancer Res. 2008; 14(20):6602-9. PMC: 2722068. DOI: 10.1158/1078-0432.CCR-08-0647. View

12.

Peto R, Davies C, Godwin J, Gray R, Pan H, Clarke M . Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2011; 379(9814):432-44. PMC: 3273723. DOI: 10.1016/S0140-6736(11)61625-5. View

13.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View

14.

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W . Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24(23):3726-34. DOI: 10.1200/JCO.2005.04.7985. View

15.

Baum M, Budzar A, Cuzick J, Forbes J, Houghton J, Klijn J . Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002; 359(9324):2131-9. DOI: 10.1016/s0140-6736(02)09088-8. View

16.

. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365(9472):1687-717. DOI: 10.1016/S0140-6736(05)66544-0. View

17.

Gnant M, Sestak I, Filipits M, Dowsett M, Balic M, Lopez-Knowles E . Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of.... Ann Oncol. 2015; 26(8):1685-91. DOI: 10.1093/annonc/mdv215. View

18.

Ramsey S, Barlow W, Gonzalez-Angulo A, Tunis S, Baker L, Crowley J . Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes. Contemp Clin Trials. 2012; 34(1):1-9. PMC: 3525786. DOI: 10.1016/j.cct.2012.09.003. View

19.

Dowsett M, Cuzick J, Wale C, Forbes J, Mallon E, Salter J . Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010; 28(11):1829-34. DOI: 10.1200/JCO.2009.24.4798. View

20.

Oratz R, Kim B, Chao C, Skrzypczak S, Ory C, Bugarini R . Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer. J Oncol Pract. 2011; 7(2):94-9. PMC: 3051869. DOI: 10.1200/JOP.2010.000046. View